TABLE 3.
Changes in Treatment Intent, Disease Stage, Investigation, Decision Making, or Management Plan
| All included |
BR after RP only* |
BR after RT only* |
||||
| Variable | Data | n | Data | n | Data | n |
| Change in treatment intent | 36 (65.5%) | 55 | 21 (56.8%) | 37 | 13 (86.7%) | 15 |
| To palliative | 18 (50.0%) | 36 | 10 (47.6%) | 21 | 6 (46.2%) | 13 |
| To curative | 18 (50.0%) | 36 | 11 (52.4%) | 21 | 7 (53.8%) | 13 |
| Change in disease stage | 36 (65.5%) | 55 | 24 (64.9%) | 37 | 10 (66.7%) | 15 |
| Upstaged | 34 (97.1%) | 35 | 23 (100%) | 23 | 9 (90.0%) | 10 |
| Downstaged | 1 (2.9%) | 35 | 0 (0.0%) | 23 | 1 (10.0%) | 10 |
| Ordering of additional diagnostic studies† | 13 (23.6%) | 55 | 6 (16.2%) | 37 | 7 (46.7%) | 15 |
| CT | 4 (30.8%) | 13 | 2 (33.3%) | 6 | 2 (28.6%) | 7 |
| MRI | 5 (38.5%) | 13 | 3 (50.0%) | 6 | 2 (28.6%) | 7 |
| Nuclear medicine | 1 (7.7%) | 13 | 1 (16.7%) | 6 | 0 (0.0%) | 7 |
| Ultrasound | 0 (0.0%) | 13 | 0 (0.0%) | 6 | 0 (0.0%) | 7 |
| Biopsy | 4 (30.8%) | 13 | 0 (0.0%) | 6 | 4 (57.1%) | 7 |
| Other‡ | 1 (7.7%) | 13 | 0 (0.0%) | 6 | 1 (14.3%) | 7 |
| Imaging results changed plans for surgery or biopsy | 14 (25.5%); NA 13 (23.6%) | 55 | 6 (16.2%); NA 10 (27.0%) | 37 | 8 (53.3%); NA 1 (6.7%) | 15 |
| Surgery or biopsy added | 9 (64.3%) | 14 | 4 (66.7%) | 6 | 5 (62.5%) | 8 |
| Surgery or biopsy cancelled | 5 (35.7%) | 14 | 2 (33.3%) | 6 | 3 (37.5%) | 8 |
| Other | 0 (0.0%) | 14 | 0 (0.0%) | 6 | 0 (0.0%) | 8 |
| Imaging results changed plans for systemic therapy | 31 (56.4%); NA 3 (5.5%) | 55 | 20 (54.1%); NA 2 (5.4%) | 37 | 9 (60.0%); NA 1 (6.7%) | 15 |
| Systemic therapy started | 23 (74.2%) | 31 | 15 (75.0%) | 20 | 6 (66.7%) | 9 |
| Systemic therapy not initiated/cancelled | 8 (25.8%) | 31 | 5 (25.0%) | 20 | 3 (33.3%) | 9 |
| Systemic therapy changed | 0 (0.0%) | 31 | 0 (0.0%) | 20 | 0 (0.0%) | 9 |
| Imaging results changed plans for radiotherapy | 26 (47.3%); NA 9 (16.4%) | 55 | 22 (59.5%); NA 6 (16.2%) | 37 | 4 (26.7%); NA 1 (6.7%) | 15 |
| Radiotherapy added | 13 (52.0%) | 25 | 11 (52.4%) | 21 | 2 (50.0%) | 4 |
| Radiotherapy cancelled | 9 (36.0%) | 25 | 8 (38.1%) | 21 | 1 (25.0%) | 4 |
| Radiotherapy prescription changed | 3 (12.0%) | 25 | 2 (9.5%) | 21 | 1 (25.0%) | 4 |
| Imaging results improved decision making | 49 (89.1%) | 55 | 33 (89.2%) | 37 | 14 (93.3%) | 15 |
| Imaging results changed subject’s management plan | 48 (87.3%) | 55 | 32 (86.5%) | 37 | 14 (93.3%) | 15 |
*
Inclusion criteria.
†
Categories are not mutually exclusive.
‡
Repeat PET a few months after start of androgen-deprivation therapy.
BR = biochemical recurrence; RP = radical prostatectomy; RT = radiation therapy; NA = not applicable.
Data are proportions.